Breaking News, Financial News

Novartis Revenues up 8% in the Quarter

Growth was mainly driven by Entresto, Kesimpta, Kisqali, Pluvicto and Scemblix.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis 4Q Revenues: $11.4 billion (+8%) 4Q Earnings: $2.6 billion (+101%) FY Revenues: $45.4 billion (+8%) FY Earnings: $8.6 billion (+42%) Comments: Sales growth in the quarter was mainly driven by continued strong performance from Entresto (+27% to $1.6 billion), Kesimpta (+74% to $641 million), Kisqali (+71% cc to $610 million), Pluvicto (+53% to $273 million) and Scemblix (+143% cc to $125 million). Cosentyx sales were $1.3 billion in the quarter, up 21%. Promacta/Revolade sales were ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters